NuVasive, Inc. (NASDAQ:NUVA) CEO James Christopher Barry Sells 5,000 Shares

NuVasive, Inc. (NASDAQ:NUVAGet Rating) CEO James Christopher Barry sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $58.00, for a total transaction of $290,000.00. Following the completion of the transaction, the chief executive officer now owns 50,218 shares of the company’s stock, valued at approximately $2,912,644. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

James Christopher Barry also recently made the following trade(s):

  • On Monday, March 28th, James Christopher Barry sold 5,000 shares of NuVasive stock. The stock was sold at an average price of $55.00, for a total transaction of $275,000.00.

Shares of NASDAQ NUVA opened at $59.75 on Friday. The company has a quick ratio of 2.42, a current ratio of 3.99 and a debt-to-equity ratio of 1.11. NuVasive, Inc. has a 1-year low of $45.45 and a 1-year high of $72.61. The company has a fifty day moving average price of $53.64 and a 200 day moving average price of $54.23.

NuVasive (NASDAQ:NUVAGet Rating) last announced its earnings results on Wednesday, February 23rd. The medical device company reported $0.40 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.07). NuVasive had a positive return on equity of 10.65% and a negative net margin of 5.63%. The company had revenue of $302.08 million during the quarter, compared to analyst estimates of $298.92 million. During the same period in the previous year, the company posted $0.59 earnings per share. NuVasive’s revenue for the quarter was up 3.5% on a year-over-year basis. As a group, sell-side analysts forecast that NuVasive, Inc. will post 2.16 earnings per share for the current fiscal year.

Several research analysts recently weighed in on the stock. Truist Financial assumed coverage on shares of NuVasive in a research report on Wednesday. They issued a “buy” rating and a $65.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of NuVasive in a report on Thursday, March 24th. Morgan Stanley lowered their target price on shares of NuVasive from $62.00 to $60.00 and set an “equal weight” rating for the company in a report on Friday, January 7th. StockNews.com started coverage on shares of NuVasive in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Wells Fargo & Company started coverage on shares of NuVasive in a report on Monday, March 28th. They set an “overweight” rating and a $58.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $64.25.

Hedge funds have recently modified their holdings of the company. Exchange Traded Concepts LLC raised its holdings in shares of NuVasive by 49.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 636 shares of the medical device company’s stock valued at $33,000 after purchasing an additional 210 shares during the period. Rockefeller Capital Management L.P. raised its holdings in shares of NuVasive by 35.3% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 1,926 shares of the medical device company’s stock valued at $115,000 after purchasing an additional 503 shares during the period. Point72 Hong Kong Ltd raised its holdings in shares of NuVasive by 3,406.6% in the 3rd quarter. Point72 Hong Kong Ltd now owns 2,139 shares of the medical device company’s stock valued at $128,000 after purchasing an additional 2,078 shares during the period. GSA Capital Partners LLP bought a new stake in shares of NuVasive in the 3rd quarter valued at about $219,000. Finally, Inspire Investing LLC bought a new stake in shares of NuVasive in the 3rd quarter valued at about $221,000. 98.06% of the stock is currently owned by institutional investors.

NuVasive Company Profile (Get Rating)

NuVasive, Inc, a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment.

Further Reading

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.